MedTrace Logo

Virtual Reality System for Anxiety and OCD

NCT03636022 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-10-15

Study results available
· View outcomes & findings →

Summary

Cognitive Behavioral Therapy with fear provoking exposures is the most effective therapy for anxiety disorders. The investigators aim to enhance this therapy with the use of virtual reality exposures. The human subjects study will test the effects of using VR for exposures compared to traditional imaginal exposures on anxiety symptom improvement, functioning, child engagement in an response to exposures, completion of exposure homework between treatment sessions, and length of treatment in weeks and length of treatment among children with anxiety disorders and/or obsessive compulsive disorder.

The funding award supports the development of the technology and the human subjects study. The subcontract to Mayo supports expert input to identify clinically relevant content for therapeutic videos on the VR system and the human subjects study to test the VR system.

Conditions

  • Anxiety
  • Obsessive-Compulsive Disorder

Interventions

OTHER

VR System

Use of virtual reality to deliver exposure therapy

OTHER

Control

Use of conventional delivery of exposure therapy

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • Minnesota HealthSolutions

    lead INDUSTRY

Principal Investigators

  • Bridget Biggs, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03636022 on ClinicalTrials.gov